Number 21

Tackling the adherence crisis

Editorial 1 November 2007 0

Two recent reports are flagging up a problem of near crisis proportions that is leading to unnecessary disease progression, reduced quality of life or even death, and costs an estimated $150– $300 billion annually in [more]

... [ more ]

Hein Van Poppel: Urological cancer is what we do

Cover Story 1 November 2007 0

Hein Van Poppel, director of the European School of Urology, is driving forward the training and accreditation of Europe’s urological oncologists. He wants to see an end to untrained urologists dishing out cancer medicines – [more]

... [ more ]

Breast screening: a question of pros and cons not right or wrong

Grandround 1 November 2007 0

Decades after breast screening programmes first started, their value remains hotly disputed. Some lives are saved, but it’s hard to tell how many. False-positives are a problem, but it’s a risk some are happy to [more]

... [ more ]

Dying for a lack of compassion?

Senza categoria 1 November 2007 0

For dying cancer patients who have run out of therapeutic options, getting hold of drugs that are still in trials can offer them a last throw of the dice. Yet many find the system for [more]

... [ more ]

The passion behind big cancer projects

Senza categoria 1 November 2007 0

Kris Vantongelen, now managing director of the Breast International Group, has played a pivotal role in two arenas that have been essential to the progress of oncology in recent decades: the development of systems for [more]

... [ more ]

Do-it-yourself Chemotherapy Access

Senza categoria 1 November 2007 0

Internet chatrooms offer patients a forum to discuss new therapies and exchange tips on how to get access to experimental drugs – sometimes from sources that have neither responsibility for nor interest in their welfare. [more]

... [ more ]

New breast care network seeks to push up standards across the globe

Spotlight on 1 November 2007 0

Cancer clinicians have a long history of collaborating across national boundaries to try to find out which therapies and protocols are most effective. Now a group of leading breast clinics have scored a first by [more]

... [ more ]

Is surgery necessary following chemoradiation for patients with locally advanced cancer of the oesophagus?

Impact Factor 1 November 2007 0

A landmark study has shown that patients with locally advanced epidermoid cancer of the oesophagus who respond well to induction chemoradiotherapy do not benefit from subsequent surgery and, therefore, seemto be well treated with definitive [more]

... [ more ]

Is rituximab maintenance therapy useful following rituximab salvage in refractory or relapsed follicular lymphoma?

Impact Factor 1 November 2007 0

A study by the German Low Grade Lymphoma Study Group has shown that rituximab maintenance following salvage with rituximab-containing chemotherapy is the standard of care for advanced-stage refractory or relapsed follicular lymphoma. Download full article

... [ more ]

N E W S R O U N D

Senza categoria 1 November 2007 0

Selected reports edited by Hannah Brown Download full article

... [ more ]

The X factor

Systems & Services 1 November 2007 0

How can cancer services deliver top-quality, affordable care to aging populations in an era of fast-changing treatments and escalating costs? Five countries with something to offer and something to learn met to compare notes. Download [more]

... [ more ]